Sugi Predict

Sugi Predict / Compounds / SCHEMBL506742

SCHEMBL506742

SCHEMBL506742

CC(C)(C)OC(=O)NCc1ccc(Cl)nc1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 4/20 0.53
▸ GAA P10253 2/20 0.51
▸ NAMPT P43490 3/20 0.50
▸ ALDH1A1 P00352 2/20 0.50
▸ FAAH O00519 1/20 0.48
▸ CYP3A4 P08684 1/20 0.46
▸ NPC1 O15118 1/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ CYP2C9 P11712 1/20 0.45
▸ MAPT P10636 3/20 0.45
▸ KDM4E B2RXH2 1/20 0.45
▸ TDP1 Q9NUW8 1/20 0.45
▸ RECQL P46063 1/20 0.45
▸ NPSR1 Q6W5P4 1/20 0.45
▸ STK17B O94768 1/20 0.44
▸ STK17A Q9UEE5 1/20 0.44
▸ TSHR P16473 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3634189 0.86 MEN1 (0.52) GAANAMPTALDH1A1NPC1RAB9A
SCHEMBL1632519 0.85 L3MBTL1 (0.53) L3MBTL1GAANAMPTCYP3A4MAPT
SCHEMBL1585183 0.85 STK17B (0.52) L3MBTL1GAANAMPTCYP3A4MAPT
SCHEMBL2580613 0.85 L3MBTL1 (0.50) L3MBTL1GAANAMPTCYP3A4MAPT
SCHEMBL30060309 0.84 HDAC3 (0.46) L3MBTL1GAANAMPTALDH1A1MAPT
SCHEMBL507338 0.84 L3MBTL1 (0.52) L3MBTL1GAANAMPTCYP3A4MAPT
SCHEMBL1432994 0.84 L3MBTL1 (0.52) L3MBTL1GAANAMPTCYP3A4MAPT
SCHEMBL1632517 0.84 L3MBTL1 (0.52) L3MBTL1GAANAMPTCYP3A4MAPT
SCHEMBL16935746 0.84 L3MBTL1 (0.52) L3MBTL1GAANAMPTCYP3A4MAPT
SCHEMBL30517227 0.84 L3MBTL1 (0.52) L3MBTL1GAANAMPTCYP3A4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12637427-B2 ALDH-2 inhibitor compounds and methods of use AMYGDALA NEUROSCIENCES, INC. (US) 2026-05-26 — — US disclosed
EP-4655294-A1 PYRAZOLE DERIVSTIVES AS PHD INHIBITORS Oxford University Innovation Limited (GB) 2025-12-03 — — EP disclosed
EP-4655288-A1 PHD INHIBITORS Oxford University Innovation Limited (GB) 2025-12-03 — — EP disclosed
EP-4540228-A1 ALDH-2 INHIBITOR COMPOUNDS AND METHODS OF USE Amygdala Neurosciences, Inc. (US) 2025-04-23 — — EP disclosed
US-20240368147-A1 CYCLIN K DEGRADER ADLAI NORTYE BIOPHARMA CO., LTD. (CN) 2024-11-07 — — US disclosed
WO-2024157019-A1 PHD INHIBITORS OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2024-08-02 — — WO disclosed
WO-2024157014-A1 PYRAZOLE DERIVSTIVES AS PHD INHIBITORS OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2024-08-02 — — WO disclosed
CN-115605477-B Pyrazolo [1,5-a ] pyridine derivative, preparation method, composition and application thereof 深圳众格生物科技有限公司 2024-07-05 — — CN disclosed
EP-4382519-A1 CYCLIN K DEGRADATION AGENT Adlai Nortye Biopharma Co., Ltd. (CN) 2024-06-12 — — EP disclosed
WO-2023244563-A1 ALDH-2 INHIBITOR COMPOUNDS AND METHODS OF USE AMYGDALA NEUROSCIENCES, INC. (US) 2023-12-21 — — WO disclosed
WO-2008067871-A1 SUBSTITUTED DIHYDROPYRAZOLONES FOR TREATING CARDIOVASCULAR AND HAEMATOLOGICAL DISEASES BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-06-12 — — WO disclosed
EP-1924561-A2 6-ARYLALKYLAMINO- 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS Eli Lilly & Company (US) 2008-05-28 — — EP disclosed
WO-2008021038-A2 PYRIDOBENZAZEPINE COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION MILLENNIUM PHARMACEUTICALS, INC. (US) 2008-02-21 — — WO disclosed
US-20080045501-A1 Pyridobenzazepine compounds and methods for inhibiting mitotic progression MILLENNIUM PHARMACEUTICALS, INC. (US) 2008-02-21 — — US disclosed
US-20080045501-A1 Pyridobenzazepine compounds and methods for inhibiting mitotic progression MILLENNIUM PHARMACEUTICALS, INC. (US) 2008-02-21 — — US disclosed
CN-1934088-A As 5-HT2c6-substituted 2,3,4, 5-tetrahydro-1H-benzo [ d ] receptor agonists]Aza * LILLY CO ELI (US) 2007-03-21 — — CN disclosed
WO-2007028083-A2 6-ARYLALKYLAMINO- 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2007-03-08 — — WO disclosed
WO-2007028083-A2 6-ARYLALKYLAMINO- 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2007-03-08 — — WO disclosed
EP-1720836-A1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2006-11-15 — — EP disclosed
WO-2005082859-A1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2005-09-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368147-A1 CYCLIN K DEGRADER CCNK, CCNI, CDK1 L3MBTL1 4467/4885GAA 1186/4885NAMPT 2294/4885
US-20080045501-A1 Pyridobenzazepine compounds and methods for inhibiting mitotic progression AURKB, AURKC, AURKA L3MBTL1 2286/4885GAA 2957/4885NAMPT 1359/4885
US-12637427-B2 ALDH-2 inhibitor compounds and methods of use ALDH3A1, ALDH1A1, ALDH1A2 L3MBTL1 2128/4885GAA 379/4885NAMPT 2590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.